Nalaganje...
Duration of nivolumab for pretreated, advanced non–small‐cell lung cancer
BACKGROUND: A standard of care for pretreated, advanced non–small‐cell lung cancers (NSCLCs), nivolumab has demonstrated long‐term benefit when administered for 2 years. We aimed to better discern an optimized administration duration by retrospectively analyzing real‐life long‐term efficacy in a pro...
Shranjeno v:
| izdano v: | Cancer Med |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
John Wiley and Sons Inc.
2020
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7541160/ https://ncbi.nlm.nih.gov/pubmed/32412157 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.3120 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|